Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.38 |
| ▸ | TK1 | P04183 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41471 | 1.00 | DUT (0.50) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL3340603 | 1.00 | DUT (0.50) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL4201158 | 1.00 | DUT (0.50) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6034458 | 0.91 | DUT (0.53) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL15771583 | 0.88 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL249821 | 0.88 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL2056622 | 0.88 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL10765602 | 0.88 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL28745696 | 0.88 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL414704 | 0.88 | DUT (0.51) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469691-B2 | Anti-cMET antibody | PIERRE FABRE MEDICAMENT (FR) | 2016-10-18 | — | — | US | disclosed |
| US-20160159911-A9 | ANTI-cMET ANTIBODY | PIERRE FABRE MEDICAMENT (FR) | 2016-06-09 | — | — | US | disclosed |
| US-20150291696-A1 | ANTI-cMET ANTIBODY | PIERRE FABRE MEDICAMENT (FR) | 2015-10-15 | — | — | US | disclosed |
| EP-2558113-A2 | SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE | Celladon Corporation (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130552-A2 | SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE | CELLADON CORPORATION (US) | 2011-10-20 | — | — | WO | disclosed |
| EP-0827552-B1 | NUCLEOTIDE SEQUENCE DETECTION WITH SIGNAL AMPLIFICATION | BIO MERIEUX (FR) | 2002-01-02 | — | — | EP | disclosed |
| US-6015694-A | INFECTING SUSCEPTIBLE ANIMAL TARGET CELLS WITH A VECTOR WHICH DIRECTS THE EXPRESSION OF AN ANTIGEN | CHIRON CORPORATION (US) | 2000-01-18 | — | — | US | disclosed |